Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 3 of 26
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Beth Israel Deaconess Medical Center
NCT06896474
E-Mindfulness Approaches for Living After Breast Cancer
NRG Oncology
NCT06748222
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
NCT07062965
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
University of Chicago
NCT03729115
Two Versus One Week Breast Radiotherapy (RT)
Weill Medical College of Cornell University
NCT06960707
Core Biopsies for Establishing a Breast Tumor Tissue Repository
University of Southern California
NCT02250352
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
NCT05715255
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
Weill Medical College of Cornell University
NCT05134779
BostonGene and Exigent Genomic INsight Study
BostonGene
NCT06272864
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
Memorial Sloan Kettering Cancer Center
NCT07220967
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NRG Oncology
NCT05896189
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics
NCT07424547
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Dana-Farber Cancer Institute
NCT04569747
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme
NCT06797635
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
Dana-Farber Cancer Institute
NCT07123649
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ana C Garrido-Castro, MD
NCT06533826
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
Columbia University
NCT05496829
Improving Comprehensive Care of Cancer Patients
Baylor College of Medicine
NCT05323409
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
Precise Oncology Interventions in Nutrition and Training (OnPoint)
University of Miami
NCT06534918
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
M.D. Anderson Cancer Center
NCT06897488
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
M.D. Anderson Cancer Center
NCT05042687
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Role of the Immune Environment in Response to Therapy in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05396612
WashU DIEP Flap Video and Patient Understanding Improvement
Washington University School of Medicine
NCT06864754
Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
University of Pittsburgh
NCT01042548
Breast Mesh Used in Two-staged Breast Reconstruction
Tianjin Medical University Cancer Institute and Hospital
NCT04967976
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06144164
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Genentech
NCT07100106
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04084730
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Proton Collaborative Group
NCT05856773
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Dana-Farber Cancer Institute
NCT05535192
ERAS Protocols in Breast Conserving Surgery
University of Nebraska
NCT06938581
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
Lauren Hamel
NCT04766190
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Duke University
NCT06371768
Patient Care Outreach, Navigation, Technology and Support 2.0
University of California, San Francisco
NCT06648278
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Laekna Limited
NCT04851613
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
UNC Lineberger Comprehensive Cancer Center
NCT06878547
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
Virginia Commonwealth University
NCT05334732
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Johns Hopkins University
NCT05780814
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
NCT05950945
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
University of California, Davis
NCT06103669
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
UNC Lineberger Comprehensive Cancer Center
NCT06096623
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
M.D. Anderson Cancer Center
NCT05766891
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.